Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 11/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2542108 | 0.83 | CYP1A2 (0.50) | CYP1A2FAAHTRPV1ALDH1A1 | |
| SCHEMBL3407690 | 0.81 | CYP1A2 (0.49) | CYP1A2FPR2 | |
| SCHEMBL1531618 | 0.81 | CYP1A2 (0.51) | CYP1A2FAAHALDH1A1SMN1; SMN2 | |
| SCHEMBL20340394 | 0.80 | CTSK (0.57) | CYP1A2FAAHTRPV1RAB9ANPC1 | |
| SCHEMBL20340446 | 0.80 | GAA (0.48) | CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL17149444 | 0.79 | CA12 (0.41) | MAPK1FPR2RAB9ANPC1ALDH1A1 | |
| SCHEMBL20340380 | 0.78 | ALDH1A1 (0.45) | CYP1A2RAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28172437 | 0.76 | CA1 (0.44) | MAPK1FPR2ALDH1A1 | |
| SCHEMBL15515607 | 0.75 | CTSL (0.58) | MAPK1HDAC1ALDH1A1SMN1; SMN2CTSL | |
| SCHEMBL16876726 | 0.74 | ALDH1A1 (0.61) | MAPK1FAAHFPR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | ENPP2, SLC10A1, CXCR3 | CYP1A2 2289/4885MAPK1 679/4885FAAH 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.